SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    [No authors listed]. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 39093918.
  • 2
    McLaughlin P,Grillo-Lopez AJ,Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program. J Clin Oncol. 1998; 16: 28252833.
  • 3
    Cessano A,Gayko U,Braman C, et al. Differential expression of CD22 indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted therapy. Blood. 2002; 100/11: 350a [abstract].
  • 4
    Clark EA. CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol. 1993; 150: 47154718.
  • 5
    Tedder TF,Poe JC,Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 2005; 88: 150.
  • 6
    Pawlak-Byczkowska EJ,Hansen HJ,Dion AS, et al. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res. 1989; 49: 45684577.
  • 7
    Stein R,Belisle E,Hansen HJ, et al. Epitope specificity of the anti-(B-cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immuother. 1993; 37: 293298.
  • 8
    Leung SO,Goldenberg DM,Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific leukemia/lymphoma antibody, LL2. Mol Immunol. 1995; 32: 14131427.
  • 9
    Gada P,Hernandez-Ilizaliturri F,Repasky EA, et al. Epratuzumab's predominant antitumor activity in vitro/in vivo against non-Hodgkin's lymphoma (NHL) is via antibody-dependent cellular cytotoxicity (ADCC) [abstract]. Blood. 2002; 100: 353a. Abstract 1367.
  • 10
    Stein R,Qu Z,Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res. 2004; 10: 28682878.
  • 11
    Hernandez-Ilizaliturri F,Gada P,Repasky EA, et al. Enhancement in anti-tumor activity of rituximab when combined with epratuzumab or apolizumab (Hu1D10) in a B-cell lymphoma severe combined immunodeficiency (SCID) mouse model [abstract]. Blood. 2002; 100: 158a. Abstract.
  • 12
    Carnahan J,Stein R,Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007; 44: 13311341.
  • 13
    Leonard JP,Coleman M,Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21: 30513059.
  • 14
    Leonard JP,Coleman M,Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004; 10: 53275334.
  • 15
    Leonard JP,Coleman M,Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 50445051.
  • 16
    Emmanouilides C,Leonard JP,Schuster SJ, et al. Multi-center phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL [abstract]. Blood. 2003; 102: 69a. Abstract.
  • 17
    Leonard JP,Schuster SJ,Emmanouilides C, et al. Durable complete responses following therapy with epratuzumab plus rituximab: final efficacy results of a multicenter study in recurrent indolent non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 2007; 110: 1002a. Abstract.
  • 18
    Cheson BD,Horning S,Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 12441253.
  • 19
    Solal-Celigny P,Roy P,Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004; 104: 12581265.
  • 20
    Harris NL,Ferry JA. Classification of non-Hodgkin's lymphomas. In: KnowlesDM, ed. Neoplastic Hematopathology,2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001: 691753.
  • 21
    Doshi S,Ngo LY,Sarikaya N, et al. Pharmacokinetics of rituximab and epratuzumab during concomitant administration of the 2 antibodies in patients with B-cell NHL [abstract]. Blood. 2003; 102: 644a. Abstract.
  • 22
    Perotti B,Doshi S,Chen D, et al. Pharmacokinetics of epratuzumab administered as a single agent or in combination with rituximab in patients with B-cell NHL [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 575. Abstract 2311.
  • 23
    Genentech. Rituxan (rituximab) full prescribing information. Available at:http://www.gene.com/gene/products/information/oncology/rituxan/insert.jsp. Accessed on October 1, 2008.
  • 24
    Czuczman MS,Weaver R,Alkuzweny B, et al. Prolonged clinical and molecular remissions in patients with low-grade follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow up. J Clin Oncol. 2004; 23: 47114716.
  • 25
    Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005; 23: 6241628.
  • 26
    Cheson DB. Hematological malignancies: new developments and future treatments. Semin Oncol. 2002; 29: 3345.
  • 27
    Leonard JP,Friedberg JW,Younes A, et al. A phase I/II study of faliximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007; 18: 12161223.
  • 28
    Maloney DG,Grillo-Lopez AJ,White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90: 21882195.
  • 29
    Strauss SJ,Morschhauser F,Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006; 24: 38803886.
  • 30
    Davis TA,Grillo-Lopez AJ,White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000; 18: 31353143.
  • 31
    Igarashi T,Ohtsu T,Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol. 2001; 73: 213221.
  • 32
    Micallef IN,Kahl BS,Maurer MJ, et al. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer. 2006; 107: 28262832.